98%
921
2 minutes
20
Existing studies in developing countries on the impact of chest pain center (CPC) accreditation on treatment quality have limited ability to demonstrate causal relationships. This retrospective study aims to utilize the data from national-level database and explore the impact of chest pain center certification on the treatment quality of ST-segment elevation myocardial infarction (STEMI) patients through a more appropriate method. At the hospital level, taking timely reperfusion and in-hospital mortality as outcomes, the impact was evaluated using the Counterfactual Synthetic Difference-in-Differences (CS-DID) method, a statistical technique that allows for the estimation of causal effects by comparing the differences over time between treated and non-treated groups. The results showed that CPC accreditation improved timely reperfusion of STEMI. Once a CPC was certified, without considering covariates, the timely reperfusion rate increased on average by 5.4%, the 90-min PCI rate by 7.1%, and the 30-min thrombolysis rate by 2.0% in comparison with non-accredited hospitals, and this effect shows a downward trend over time and varies between different regions. We found no evidence to confirm that CPC accreditation decreases in-hospital mortality in patients with STEMI. CPC accreditation in China has improved the timeliness of reperfusion therapy for STEMI patients. CPC accreditation and re-accreditation are crucial to maintaining high-quality care for STEMI patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084382 | PMC |
http://dx.doi.org/10.1038/s41598-025-02151-3 | DOI Listing |
J Am Coll Cardiol
September 2025
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Background: Genetic variants in cardiomyopathy genes are associated with risk of atrial fibrillation (AF), although data on clinical outcomes for AF patients with such variants remain sparse.
Objectives: We aimed to study the prognostic implication of rare cardiomyopathy-associated pathogenic variants (CMP-PLP) in AF patients from large, well-phenotyped clinical trials.
Methods: CMP-PLP carriers were identified using exome sequencing in 5 multinational trials from the Thrombolysis in Myocardial Infarction study group (ENGAGE AF, FOURIER, SAVOR, PEGASUS, and DECLARE), with replication in the EAST-AFNET-4 trial.
J Am Coll Cardiol
August 2025
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Background: The clinical utility of a heart failure (HF) polygenic risk score (PRS) is uncertain.
Objectives: The purpose of this study was to investigate the ability of an HF PRS to predict new-onset HF in individuals across the spectrum of cardiovascular risk.
Methods: An HF PRS (>1 million single nucleotide variations) was used to stratify individuals from 7 clinical studies to low (quintile [Q] 1), intermediate (Q2-Q4), or high (Q5) genetic risk.
Sci Rep
May 2025
Department of Biostatistics, School of Public Health, Harbin Medical University, No.157 Baojian Road, Harbin City, 150081, Heilongjiang Province, China.
Existing studies in developing countries on the impact of chest pain center (CPC) accreditation on treatment quality have limited ability to demonstrate causal relationships. This retrospective study aims to utilize the data from national-level database and explore the impact of chest pain center certification on the treatment quality of ST-segment elevation myocardial infarction (STEMI) patients through a more appropriate method. At the hospital level, taking timely reperfusion and in-hospital mortality as outcomes, the impact was evaluated using the Counterfactual Synthetic Difference-in-Differences (CS-DID) method, a statistical technique that allows for the estimation of causal effects by comparing the differences over time between treated and non-treated groups.
View Article and Find Full Text PDFJACC Adv
June 2025
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Background: Racial and ethnic disparities in cardiovascular disease outcomes, including percutaneous coronary intervention (PCI), are well-documented. However, studies do not stratify certain subgroups, such as separating South Asian and East Asian patients, who exhibit varying burdens of cardiovascular disease and PCI outcomes. Additionally, socioeconomic status (SES) further complicates outcomes, with low SES serving as an independent predictor of adverse outcomes post-PCI.
View Article and Find Full Text PDF